Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health Freedom Protection Act, take two

This article was originally published in The Tan Sheet

Executive Summary

Ron Paul, R-Texas, and others reintroduced the Health Freedom Protection Act, H.R. 2117, May 1. Paul first introduced the bill in November 2005 (1"The Tan Sheet" Nov. 14, 2005, p. 10). The bill seeks to amend the Food, Drug and Cosmetic Act to allow broader dietary supplement claims, even venturing into the drug arena. The bill also seeks a more rapid response to health claims - after 100 days if there is no response from the HHS secretary the claims would be allowed. The legislation also proposes FTC must notify advertisers before the agency conducts an investigation and give 30 days for companies to discontinue their ads...

You may also be interested in...



Greater Claims Leeway Proposed By Health Freedom Protection Act

A bill introduced in Congress Nov. 9 would "prevent FDA from disallowing structure function claims that include terms that refer to signs or symptoms of disease so long as the disease itself is not mentioned.

Genus Triumphs Over FDA In Barium Sulfate Product Classification Suit

The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.

Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis

Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.

Topics

UsernamePublicRestriction

Register

PS100479

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel